Intravenous enzyme substitution in Fabry's disease in children;Intravenøs enzymsubstitusjonsbehandling ved Fabrys sykdom hos barn

Tidsskrift for den Norske Laegeforening

Volumn 123, Issue 23, 2003, Pages 3388-3390

  Tøndel, Camilla ^a   Lægreid, Liv Marie ^a   Hirth, Asle ^a   Houge, Gunnar ^a   Månsson, Jan Eric ^b   Søvik, Oddmund ^a,c  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA; ALPHA GALACTOSIDASE; GLOBOTRIAOSYLCERAMIDE; ISOENZYME;

ABDOMINAL PAIN; ADOLESCENT; ARTICLE; BIOACCUMULATION; CASE REPORT; CELL LEVEL; DIARRHEA; DRUG EFFICACY; ECHOCARDIOGRAPHY; ENDOTHELIUM CELL; ENZYME REPLACEMENT; FABRY DISEASE; FEVER; GENE DELETION; HUMAN; LEUKOCYTE; LYSOSOME STORAGE DISEASE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PARESTHESIA; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN BURNING SENSATION; SYMPTOM; URINE LEVEL; VASCULAR ENDOTHELIUM; X CHROMOSOME LINKED DISORDER; CHILD; ECHOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; PATHOLOGY;

ADOLESCENT; ALPHA-GALACTOSIDASE; CHILD; ECHOCARDIOGRAPHY; FABRY DISEASE; HUMANS; INJECTIONS, INTRAVENOUS; ISOENZYMES; MAGNETIC RESONANCE IMAGING; MALE;

EID: 1442310662     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med 1967; 276: 1163-7.
2. Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 1999; 105: 151-6.
3. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999; 281: 249-54.
4. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001; 38: 769-75.
5. Spaeth GL, Frost P. Fabry's disease. Its ocular manifestations. Arch Ophthalmol 1965; 74: 760-9.
6. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001; 38: 750-60.
7. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S et al. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med 2001; 345: 9-16.
8. Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001; 285: 2743-9.
9. Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 2002; 62: 1933-46.
10. Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 2002; 113: 112-9.
11. Skare S, Gjøsund H, Skarbøvik AJ, Hovig T, Øystese B. Fabrys sykdom (angiokeratoma corporis diffusum). Tidsskr Nor Lægeforen 1979; 99: 159-62.
12. Shelley ED, Shelley WB, Kurczynski TW. Painful fingers, heat intolerance, and telangiectases of the ear: easily ignored childhood signs of Fabry disease. Pediatr Dermatol 1995; 12: 215-9.
13. Syed NA, Sandbrink F, Luciano CA, Altarescu G, Weibel T, Schiffmann R et al. Cutaneous silent periods in patients with Fabry disease. Muscle Nerve 2000; 23: 1179-86.
14. Luciano CA, Russell JW, Banerjee TK, Quirk JM, Scott LJ, Dambrosia JM et al. Physiological characterization of neuropathy in Fabry's disease. Muscle Nerve 2002; 26: 622-9.
15. Desnick RJ, Wasserstein MP. Fabry disease: clinical features and recent advances in enzyme replacement therapy. Adv Nephrol Necker Hosp 2001; 31: 317-39.
16. Argoff CE, Barton NW, Brady RO, Ziessman HA. Gastrointestinal symptoms and delayed gastric emptying in Fabry's disease: response to metoclopramide. Nucl Med Commun 1998; 19: 887-91.
17. Sher NA, Letson RD, Desnick RJ. The ocular manifestations in Fabry's disease. Arch Ophthalmol 1979; 97: 671-6.
18. Linhart A, Palecek T, Bultas J, Ferguson JJ, Hrudova J, Karetova D et al. New insights in cardiac structural changes in patients with Fabry's disease. Am Heart J 2000; 139: 1101-8.
19. Sachdev B, Takenaka T, Teraguchi H, Tei C, Lee P, McKenna WJ et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 2002; 105: 1407-11.
20. Goldman ME, Cantor R, Schwartz MF, Baker M, Desnick RJ. Echocardiographic abnormalities and disease severity in Fabry's disease. J Am Coll Cardiol 1986; 7: 1157-61.
21. Crutchfield KE, Patronas NJ, Dambrosia JM, Frei KP, Banerjee TK, Barton NW et al. Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology 1998; 50: 1746-9.
22. Moore DF, Altarescu G, Pursley R, Campia U, Panza JA, Dimitriadis E et al. Arterial Wall Properties and Wormersley Flow in Fabry Disease. BMC Cardiovasc Disord 2002; 2: 1.
23. Moore DF, Altarescu G, Herscovitch P, Schiffmann R. Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease. BMC Neurol 2002; 2: 4.
24. DeGraba T, Azhar S, Dignat-George F, Brown E, Boutiere B, Altarescu G et al. Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol 2000; 47: 229-33.
25. Pastores GM, Thadhani R. Enzyme-replacement therapy for Anderson-Fabry disease. Lancet 2001; 358: 601-3.